Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors
Source : https://ar.iiarjournals.org/content/42/10/4867
Background/Aim: The aim of this study was to elucidate the clinical significance of peripheral blood biomarkers, including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and C-reactive protein...
Conclusion: ALC is an independent prognostic factor for estrogen receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer patients treated with the CDK4/6 inhibitors abemaciclib and palbociclib.
Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction
Source : https://www.clinical-breast-cancer.com/article/S1526-8209(20)30181-6/fulltext
Micro-AbstractA 20-year retrospective review of locoregional recurrences, secondary cancers, and atypical breast neoplasms after autologous tissue reconstruction for cancer of the breast identified an overall recurrence rate of 5.3%. The...
Conclusion: Our retrospective review found incidence and survival after treatment of breast cancer concordant with reports in the literature. We also identified and analyzed secondary neoplasms, including a unique case of undifferentiated pleomorphic sarcoma and metachronous recurrence of breast carcinoma. A case of recurrence as metaplastic...
-
Albert Dekker3yrthere is huge variability in this and hard to know what really happened.
Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer | Miyahara | World Journal of Oncology
Source : https://www.wjon.org/index.php/WJON/article/view/1511
Kana Miyahara, Kazutaka Narui, Yukari Uemura, Akimitsu Yamada, Kazuhiro Araki, Fumie Fujisawa, Takahiro Nakayama, Takashi Ishikawa, Naruto Taira, Yuichiro Kikawa, Tomohiko Aihara, Hirofumi Mukai Abstract Background: Combination therapy with cyclin-dependent...
Discussion: In this multi-institutional prospective cohort study, we evaluate the clinical efficacy and safety of combination therapy with abemaciclib and hormonal therapy for chemotherapy-treated patients with HR HER2- MBC. We also evaluate this combination therapy as maintenance therapy in patients who respond to early-line chemotherapy.
-
Albert Dekker3yrI have used this approach in practice; not any different from Faslodex or Femara. Much more toxic though
Comparison of ultrasound and mammography for early diagnosis of breast cancer among Chinese women with suspected breast lesions: A prospective trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36177910/
doi: 10.1111/1759-7714.14666. Online ahead of print. 1 Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. Free article Background:...
Conclusions: Ultrasound is more sensitive and accurate than mammography and detects more breast cancers with a lower specificity.
-
Albert Dekker3yrdoes breast size matter? also how about unnecessary biopsies etc;
A Likely Case of Abemaciclib-Induced Hyperpigmentation in a Patient With Metastatic Breast Cancer
We report a case of a 64-year-old female with a past medical history of invasive right breast adenocarcinoma presented with diffuse hyperpigmentation of her skin after admission to the hospital...
Conclusion/Relevance: The literature that exists on cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6) is minimal. And so, the importance of shedding light on its possible cutaneous side effects is not only helpful for clinician diagnosis but also essential for patients to make informed decisions. To our knowledge, there is no other published...
-
Albert Dekker3yrthis class is till very new and a lot of new rare side effects not well described yet